Site icon pharmaceutical daily

2022 Global Dry Age-Related Macular Degeneration Clinical Trial Pipeline Highlights Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Dry Age-Related Macular Degeneration Clinical Trial Pipeline Highlights – 2022” report has been added to ResearchAndMarkets.com’s offering.

This report provides the most up-to-date information on key pipeline products within the global Dry Age-Related Macular Degeneration market.

It covers emerging therapies for Dry Age-Related Macular Degeneration in active clinical development stages including early and late stage clinical trials.

The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Dry Age-Related Macular Degeneration pipeline products by clinical trial stages including both early and late stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Dry Age-Related Macular Degeneration pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Dry Age-Related Macular Degeneration pipeline products by the company.

Short-term Launch Highlights:

Find out which Dry Age-Related Macular Degeneration pipeline products will be launched in the US and Ex-US till 2025.

Key Topics Covered:

1. Dry Age-Related Macular Degeneration Pipeline by Stages

2. Dry Age-Related Macular Degeneration Phase 3 Clinical Trial Insights

3. Dry Age-Related Macular Degeneration Phase 2 Clinical Trial Insights

4. Dry Age-Related Macular Degeneration Phase 1 Clinical Trial Insights

5. Dry Age-Related Macular Degeneration Preclinical Research Insights

6. Dry Age-Related Macular Degeneration Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/uwfjqd

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version